Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression (Q36676341)

15 August 2017

Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression (English)

1 reference

15 August 2017

0 references

1 reference

1 reference

Charlotte Kuperwasser

7

object named as

Charlotte Kuperwasser

1 reference

15 August 2017

Thuy L Phung

1

1 reference

15 August 2017

Godfred Eyiah-Mensah

2

1 reference

15 August 2017

Rebekah K O'Donnell

3

1 reference

15 August 2017

Radoslaw Bieniek

4

1 reference

15 August 2017

Sharon Shechter

5

1 reference

15 August 2017

Kenneth Walsh

6

1 reference

15 August 2017

Laura E Benjamin

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

15 August 2017

1 reference

15 August 2017

67

1 reference

15 August 2017

11

1 reference

15 August 2017

5070-5075

1 reference

Drug penetration in solid tumours

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Microvascular patterning is controlled by fine-tuning the Akt signal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Upstream and downstream of mTOR

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

The anti-angiogenic basis of metronomic chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

The TOR pathway: a target for cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Reconstruction of functionally normal and malignant human breast tissues in mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

The tumor microenvironment: a critical determinant of neoplastic evolution

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Tumor-associated endothelial cells with cytogenetic abnormalities.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2396346

Meeting report: exploiting the tumor microenvironment for therapeutics

20 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17545582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17545582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17545582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/0008-5472.CAN-06-3341

1 reference

15 August 2017

1 reference

15 August 2017

1 reference